• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aeterna Zentaris Inc.

    6/6/24 1:46:51 PM ET
    $AEZS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEZS alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. ______)*

     

    Aeterna Zentaris Inc.

    (Name of Issuer)

     

    Common Stock, no par value

    (Title of Class of Securities)

     

    007975600

    (CUSIP Number)

     

    May 29, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

      

    CUSIP No. 007975600   Schedule 13G   Page 2 of 8

     

    1. Names of Reporting Persons.

    Goodwood Fund

     

    2. Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

     

    3. SEC Use Only

     

    4. Citizenship or Place of Organization

    Province of Ontario, Canada

     

     

    5. Sole Voting Power

    -0-

     

    Number of Shares Beneficially

    Owned by

    6. Shared Voting Power

    225,150

     

    Each Reporting

    Person With:

    7. Sole Dispositive Power

    -0-

     

    8. Shared Dispositive Power

    225,150

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person

    225,150

     

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

    11. Percent of Class Represented by Amount in Row (9)

    7.2%

     

    12. Type of Reporting Person

    CO

     

     

     

     

    CUSIP No. 007975600   Schedule 13G   Page 3 of 8

     

    1. Names of Reporting Persons.

    Goodwood, Inc.

     

    2. Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

     

    3. SEC Use Only

     

    4. Citizenship or Place of Organization

    Province of Ontario, Canada

     

     

    5. Sole Voting Power

    -0-

     

    Number of Shares Beneficially

    Owned by

    6. Shared Voting Power

    225,150

     

    Each Reporting

    Person With:

    7. Sole Dispositive Power

    -0-

     

     

    8. Shared Dispositive Power

    225,150

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person

    225,150

     

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

    11. Percent of Class Represented by Amount in Row (9)

    7.2%

     

    12. Type of Reporting Person

    OO

     

     

     

     

    CUSIP No. 007975600   Schedule 13G   Page 4 of 8

     

    1. Names of Reporting Persons.

    Peter Puccetti.

     

    2. Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

     

    3. SEC Use Only

     

    4. Citizenship or Place of Organization

    Canada

     

     

    5. Sole Voting Power

    -0-

     

    Number of Shares Beneficially

    Owned by

    6. Shared Voting Power

    225,150

     

    Each Reporting

    Person With:

    7. Sole Dispositive Power

    -0-

     

    8. Shared Dispositive Power

    225,150

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person

    225,150

     

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

    11. Percent of Class Represented by Amount in Row (9)

    7.2%

     

    12. Type of Reporting Person

    IN

     

     

     

     

    CUSIP No. 007975600

     

    ITEM 1.

     

    (a)Name of Issuer:

     

    Aeterna Zentaris Inc.

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    c/o Norton Rose Fulbright Canada, LLP

    222 Bay Street, Suite 3000

    PO Box 53

    Toronto ON M5K 1E7, Canada

     

    ITEM 2.

     

    (a)Name of Person Filing:

     

    (b)Address of Principal Business Office, or if None, Residence:

     

    (c)Citizenship:

     

    Goodwood Fund

    132 Trafalgar Road

    Oakville, Ontario L6J 3G5

    Place of Organization: Province of Ontario, Canada

     

    Goodwood Inc.

    132 Trafalgar Road

    Oakville, Ontario L6J 3G5

    Place of Organization: Province of Ontario, Canada

     

    Peter Puccetti

    132 Trafalgar Road

    Oakville, Ontario L6J 3G5

    Citizenship: Canada

     

    (d)Title of Class of Securities:

     

    Common stock, no par value

     

    (e)CUSIP Number:

     

    007975600

     

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

     

     

     

     

    ITEM 4. OWNERSHIP

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount Beneficially Owned:

     

    As of the close of business on June 5, 2024:

     

    Goodwood Fund beneficially owned 225,150 shares of the issuer’s common stock, or 7.2% of the issuer’s common stock outstanding, consisting of 178,680 outstanding shares held directly by Goodwood Fund and warrants to purchase 46,470 shares held directly by Goodwood Fund.

     

    Goodwood Inc., as the investment manager of Goodwood Fund, beneficially owned 225,150 shares of the issuer’s common stock, or 7.2% of the issuer’s common stock outstanding, consisting of 178,680 shares and 46,470 warrants held directly by Goodwood Fund.

     

    Peter Puccetti, as principal and control person of Goodwood, Inc, beneficially owned 225,150 shares of the issuer’s common stock, or 7.2% of the issuer’s common stock outstanding, consisting of 178,680 shares and 46,470 warrants held directly by Goodwood Fund.

     

    (b) Percent of Class:

     

    As of the close of business on June 5, 2024, the reporting persons may be deemed to beneficially own 225,150 shares of the issuer’s common stock or 7.2% of the issuer’s common stock outstanding (see Item 4(a) above), which percentage was calculated based on 3,061,688 shares of the issuer’s common stock outstanding as of June 5, 2024, as reported in the issuer’s Post-Effective Amendment No. 5 To Form F-1 filed May 31, 2024, plus 46,470 shares issuable under warrants held by Goodwood Fund as of June 5, 2024.

     

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

     

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Not applicable.

     

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     

    Not applicable.

     

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

     

    See Exhibit I.

     

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable.

     

    ITEM 10. CERTIFICATIONS

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: June 5, 2024

     

    GOODWOOD FUND

     

    By: Goodwood, Inc., its Manager

     

    By: /s/ Peter Puccetti  
    Name: Peter Puccetti  
    Title: Chairman & Chief Investment Officer  

     

    GOODWOOD INC.  

     

    By: /s/ Peter Puccetti  
    Name: Peter Puccetti  
    Title: Chairman & Chief Investment Officer  

     

    /s/ Peter Puccetti  
    Name: Peter Puccetti  

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

     

     

     

    EXHIBIT I

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the common stock, no par value, of Aeterna Zentaris Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.

     

    The undersigned further agree that each party hereto is responsible for the timely filing of the Schedule 13G, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has a reason to believe that such information is inaccurate.

     

    It is understood and agreed that a copy of this Joint Filing Agreement shall be attached as an exhibit to the Schedule 13G, filed on behalf of each of the parties hereto.

     

    IN WITNESS WHEREOF, each of the undersigned has executed this Joint Filing Agreement as of the 5th day of June, 2024.

     

    GOODWOOD FUND

     

    By: Goodwood, Inc., its Manager

     

    By: /s/ Peter Puccetti  
    Name: Peter Puccetti  
    Title: Chairman & Chief Investment Officer  

     

    GOODWOOD INC.  

     

    By: /s/ Peter Puccetti  
    Name: Peter Puccetti  
    Title: Chairman & Chief Investment Officer  

     

    /s/ Peter Puccetti  
    Name: Peter Puccetti  

     

     

    Get the next $AEZS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AEZS

    DatePrice TargetRatingAnalyst
    10/25/2021$2.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AEZS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

      TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ:AEZS) (TSX:AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announces that the Company's name has been changed from "Aeterna Zentaris Inc." to "COSCIENS Biopharma Inc.", effective as of August 6, 2024 (the "Name Change"). In addition, the Company announces that, effective as of August 9, 2024, the Company's common shares (the "Common Shares") will begin trading on the Toronto Stock

      8/6/24 6:00:00 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

      TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the "AGSM") held today. Results of the AGSM The results of the vote in respect of the election of directors of the Company are set out below: Name of NomineeVotes For% ForVotes Against% AgainstRon

      7/16/24 4:05:00 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products

    $AEZS
    Leadership Updates

    Live Leadership Updates

    See more
    • Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

      TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the "AGSM") held today. Results of the AGSM The results of the vote in respect of the election of directors of the Company are set out below: Name of NomineeVotes For% ForVotes Against% AgainstRon

      7/16/24 4:05:00 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer

      – Well-established finance professional with over 20 years of experience gained in pharmaceutical, biopharma and professional services sectors TORONTO, ONTARIO, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced the appointment of Giuliano La Fratta as Senior Vice President, Chief Financial Officer. Effective January 24th, 2022, Mr. La Fratta will be responsible for the finance-related leadership functions, succeeding Ms. Leslie Auld, the Company's current Senior Vice President,

      12/23/21 4:05:00 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEZS
    SEC Filings

    See more

    $AEZS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 6-K filed by Aeterna Zentaris Inc.

      6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

      8/13/24 8:05:36 AM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Aeterna Zentaris Inc.

      6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

      8/13/24 8:05:17 AM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Aeterna Zentaris Inc.

      6-K - Aeterna Zentaris Inc. (0001113423) (Filer)

      8/6/24 6:22:58 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aeterna Zentaris Inc.

      SC 13G - Aeterna Zentaris Inc. (0001113423) (Subject)

      6/6/24 1:46:51 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aeterna Zentaris Inc. (Amendment)

      SC 13G/A - Aeterna Zentaris Inc. (0001113423) (Subject)

      2/11/22 6:41:14 AM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Aeterna Zentaris Inc. (0001113423) (Subject)

      2/16/21 2:50:58 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEZS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on AEterna Zentaris with a new price target

      HC Wainwright & Co. initiated coverage of AEterna Zentaris with a rating of Buy and set a new price target of $2.00

      10/25/21 6:23:09 AM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care